Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18944058 | 1.00 | ELANE (0.34) | ELANENPC1SMN1; SMN2POLBGAA | |
| SCHEMBL24281977 | 1.00 | ELANE (0.34) | ELANENPC1SMN1; SMN2POLBGAA | |
| SCHEMBL26201117 | 0.84 | ALDH1A1 (0.34) | ALDH1A1CYP3A4 | |
| SCHEMBL26201180 | 0.77 | ELANE (0.35) | ELANENPC1SMN1; SMN2POLBGAA | |
| SCHEMBL821222 | 0.75 | TDP1 (0.46) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL18944183 | 0.75 | TDP1 (0.46) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL24281979 | 0.75 | TDP1 (0.46) | SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL821494 | 0.74 | ELANE (0.33) | ELANENPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31320358 | 0.74 | ELANE (0.33) | ELANENPC1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17388254 | 0.74 | ELANE (0.33) | ELANENPC1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2023-08-31 | — | — | US | disclosed |
| WO-2022061461-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | TETRA BIO-PHARMA INC. (CA) | 2022-03-31 | — | — | WO | disclosed |
| WO-2017093749-A1 | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED CANNABINOID COMPOUNDS | E-THERAPEUTICS PLC (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-9428431-B2 | Compositions comprising CB receptor agonists, uses thereof and methods for their preparation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | PHARMOS CORPORATION | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269842-A1 | COMPOSITIONS COMPRISING CB RECEPTOR AGONISTS, USES THEREOF AND METHODS FOR THEIR PREPARATION | CNR1, CNR2, ADRA2C | ELANE 3436/4885NPC1 734/4885SMN1; SMN2 1825/4885 |
| US-20070060636-A1 | High enantiomeric purity dexanabinol for pharmaceutical compositions | CNR2, CNR1, PDE8B | ELANE 1995/4885NPC1 2119/4885SMN1; SMN2 536/4885 |
| US-20230271908-A1 | METHODS, PROCESSES, AND COMPOSITIONS FOR IMPROVED PREPARATION OF HU308 AND HU433 | CYP3A43, PRMT8, MGMT | ELANE 1084/4885NPC1 3226/4885SMN1; SMN2 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.